Literature DB >> 870337

3-Amino-1-(3,4-dichloro-alpha-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821), a potent diuretic from a new substance class.

E Möller, H Horstmann, K Meng, D Loew.   

Abstract

Chemistry, salidiuretic activity and mechanism of action of 3-amino-1-(3,4-dichloro-alpha-methyl-benzyl)-2-pyrazolin-5-one (Bay g 2821), a new diuretic, are described. Owing to the initial rapid onset of activity, the reserve in capacity and the additional long duration of activity, this substance represents a potent diuretic and antihypertensive agent.

Entities:  

Mesh：

Substances：

Year:  1977        PMID： 870337     DOI： 10.1007/bf02002840

Source DB:  PubMed          Journal:  Experientia        ISSN： 0014-4754


  9 in total

1.  [THE SALIDIURETIC EFFECT OF 4-CHLORO-N-(2-FURFURYLMETHYL)-5-SULFAMOYLANTHRANILIC ACID].

Authors:  R MUSCHAWECK; P HAJDU
Journal:  Arzneimittelforschung       Date:  1964-01

2.  RENOTROPIC CHARACTERISTICS OF ETHACRYNIC ACID: A PHENOXYACETIC SALURETIC-DIURETIC AGENT.

Authors:  K H BEYER; J E BAER; J K MICHAELSON; H F RUSSO
Journal:  J Pharmacol Exp Ther       Date:  1965-01       Impact factor: 4.030

3.  [Hygroton (G 33,182), a new saluretic and diuretic with protracted action].

Authors:  E G STENGER; H WIRZ; R PULVER
Journal:  Schweiz Med Wochenschr       Date:  1959-10-24

4.  Studies on the mechanism of diuretic action of chlorothiazide.

Authors:  R F PITTS; F KRUCK; R LOZANO; D W TAYLOR; O P HEIDENREICH; R H KESSLER
Journal:  J Pharmacol Exp Ther       Date:  1958-06       Impact factor: 4.030

5.  Pharmacological properties of 3-n-butylamino-4-phenoxy-5-sulfamylbenzoic acid (Bumetanide), a new potent diuretic.

Authors:  E H Ostergaard; M P Magnussen; C K Nielsen; E Eilertsen; H H Frey
Journal:  Arzneimittelforschung       Date:  1972-01

6.  [Pharmacology of N-(4'-chlore-3'-sulfameyl-benzelsulfenyl)-N-methyl-2-aminomethyl-2-methyl-tetrahydrefuran, a new diuretically active compound].

Authors:  K Meng; G Kroneberg
Journal:  Arzneimittelforschung       Date:  1967-06

7.  [THE NEW SALURETIC BRINALDIX (DT-327)].

Authors:  E FLUECKIGER; W SCHALCH; M TAESCHLER
Journal:  Schweiz Med Wochenschr       Date:  1963-08-31

8.  ALPHA, BETA-UNSATURATED KETONE DERIVATIVES OF ARYLOXYACETIC ACIDS, A NEW CLASS OF DIURETICS.

Authors:  E M SCHULTZ; E J CRAGOE; J B BICKING; W A BOLHOFER; J M SPRAGUE
Journal:  J Med Pharm Chem       Date:  1962-05

9.  Aminobenzoic acid diuretics. 2. 4-Substituted-3-amino-5-sulfamylbenzoic acid derivatives.

Authors:  P W Feit
Journal:  J Med Chem       Date:  1971-05       Impact factor: 7.446
  9 in total
  6 in total

1.  A study on the effects of some drugs on DOCA induced hypertension in the rat.

Authors:  E Lampa; F Rossi; A Aliperta; L Giordano; D Perna; E Catena; E Marmo
Journal:  Experientia       Date:  1980-02-15

2.  Comparison of the effects of muzolimine and furosemide in patients with end-stage renal failure on chronic dialysis.

Authors:  P Schmidt; D Loew; J Dycka; H Kopsa; P Balcke; J Zazgornik; E Deutsch
Journal:  Eur J Clin Pharmacol       Date:  1981       Impact factor: 2.953

3.  BTS 39542, a dihydrophthalazin-1-ylacetic acid with high efficacy diuretic activity.

Authors:  M J Cooling; M F Sim
Journal:  Br J Pharmacol       Date:  1981-10       Impact factor: 8.739

4.  Comparison of the pharmacodynamic effect of muzolimine and furosemide in patients with advanced chronic renal insufficiency.

Authors:  P Schmidt; D Loew; J Dýcka; H Kopsa; P Balcke; J Zazgornik; E Deutsch
Journal:  Eur J Clin Pharmacol       Date:  1978-12-18       Impact factor: 2.953

5.  Pharmacokinetics of a single oral dose of muzolimine in cardiac failure.

Authors:  O Brørs; S Jacobsen; E Arnesen
Journal:  Eur J Clin Pharmacol       Date:  1979-03-26       Impact factor: 2.953

6.  Antihypertensive mechanism of the diuretic muzolimine in mild renal failure. Roles of sodium and cardiovascular norepinephrine responsiveness.

Authors:  H Schiffl; P Weidmann; C Beretta-Piccoli; C Cottier; A J Seiler; W H Ziegler
Journal:  Eur J Clin Pharmacol       Date:  1982       Impact factor: 2.953
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.